Kornimate/medical-research-clean huggingface dataset:
comparison of the short-term effect of dietary carbohydrate restriction versus exogenous ketone supplementation on myocardial glucose suppression and timing to achieve a state of ketosis using fdg pet/ct serial imaging

Conditions: Healthy

Summary: the purpose of this study is to test different methods of preparation that can be used prior to a test called an fdg pet/ct scan. fdg pet/ct scans are routinely done for evaluation of heart inflammation. standard preparation for the scan includes a ketogenic (high fat and low carbohydrate) diet for 24 hours and overnight fasting to help suppress the amount of sugar taken up in the heart muscle. however, investigator still do not know if this preparation is the most effective method. so the investigator, want to investigate alternative methods for decreasing the amount of sugar uptake seen in the heart during fdg pet/ct scan, thus, investigator will have participants try up to 3 different methods of preparation prior to the fdg pet/ct scans to see which type of preparation works the best.


Eligibility criteria:
inclusion criteria: 1. adult patients, at least 18 years of age 2. no history of cardiovascular disease, including hypertension, hyperlipidemia, coronary artery disease, cardiac surgery, arrhythmias per medical record review and/or self-report 3. no history of diabetes mellitus, chronic liver or kidney disease per medical record review and/or self-report. 4. participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. exclusion criteria: 1. females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. female participants of child-bearing potential will have a urine or serum pregnancy test before the first study visit. 2. inability to tolerate imaging procedures in the opinion of the investigator or treating physician. 3. serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
protocol for an analytical study with microbiological, phenotypic, genotypic and multiomics techniques

Conditions: Back Pain, Low; Degenerative Disc Disease

Summary: the study aims to identify metabolites present in intervertebral discs colonized by c. acnes from patients with low back pain and degenerative disc disease, correlating them with their clinical, radiological and demographic profiles.


Eligibility criteria:
inclusion criteria: * low back pain lasting longer than 3 months; * mri findings of degenerative lumbar discopathy (ddl) performed less than 6 months after inclusion in the study; * indication for open surgical treatment, with isolated microdiscectomy or associated with lumbar arthrodesis; * failure of conservative treatment for at least 6 weeks and/or progressive neurological deficit exclusion criteria: * history of open lumbar spine surgery at any stage of life; * presence of chemotherapy or pulse therapy with corticoids; * patients with immune deficiency; * patients undergoing previous intradiscal therapies (nucleotomy or discography); * patients undergoing previous endoscopic surgery; * patients with a history of previous spinal infection treated with antibiotics in the 6 months prior to inclusion in the study; * use of antibiotics in the 2 months prior to the surgical procedure
study to assess the efficacy and safety of the medical device iracross versus iraline administered intra-articular to patients with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: comparison with a non-inferiority design at 12 and 24 weeks on a larger scale is real to objectively evaluate the composite measurement of rom, pain and basic activities like walking or performing daily activities (qol) in a population with a large coverage of age and levels of physical activity (from no physical activity history to athletes).

after giving their consent, subjects will undergo a screening visit to determine eligibility for study entry. after randomization, subjects will have administered medical device iracross or iraline. for subjects allocated to iracross, medical device will be administered only at first visit and for subjects allocated to iraline, medical device will be administered at visit 1, visit,2, visit 3 and optional for visit 4 and visit 5.

Eligibility criteria:
inclusion criteria: 1. aged between 40 and 80 years 2. symptomatic knee osteoarthritis as defined by the american college of rheumatology (acr) criteria; (for subjects with oa at both knees, the most painful one will be included in the study only, respecting kl grade ii or iii); 3. ambulant without assistance; 4. kellgren-lawrence grade ii or iii on x-ray performed at maximum 6 months before screening; 5. vas knee pain ≥40 at screening and 30 days before; 6. at least 30 days before screening oral/parenteral corticosteroid or nsaids (10 mg prednisone) administration. 7. signed informed consent exclusion criteria: 1. unstable knee; 2. varus or valgus ≥ 15 degrees; 3. active malignancy; 4. knee trauma or lose body parts 1 year before screening; 5. rheumatoid arthritis, avascular necrosis, fibromyalgia; 6. use of potent analgesics 15 days (different from ≤ 10 mg prednisone); 7. intra-articular ha or corticosteroid injection within 6 months before screening; 8. arthroscopic or knee open surgery within 12 months before screening; 9. body mass index (bmi) ≥ 40 kg/m2; 10. active infection around the injection site; 11. use of anticoagulants or history of thrombocytopenia; 12. concomitant use of disease-modifying antirheumatic drugs (dmards), anaesthetics; 13. known sensitivity to ha or dvs; 14. pregnancy, breast feeding.
effects of miofascial release and percutaneous microeletrolysis in type headache

Conditions: Trigger Point; Tension-Type Headache

Summary: a headache is a more common disorder and one that prevails over a lifetime of much of the population. among the causes are in the stress and spasms of the pericranial musculature, presence of painful sensitivity in the region, decrease of pain threshold, and a presence of trigger points (pgs) that can also cause as headaches. the solutions for health and health, in addition to percutaneous microelectrolysis (mep®), which is used in the application of low intensity galvanic current through the acupuncture needle. although it is a very common pathology, it is still little studied and a lack of information is a question of solutions such as crisis of care. this work justifies the negative bones of ctt in university students, as this has repercussions on the quality of life, besides proposing a therapeutic approach to reduce the symptomatology. the present study aims to investigate the effects of myofascial release techniques, mep® and an association of therapies, observing the impact on quality of life and repercussions on academic performance. this is a controlled clinical trial of a convenience-based approach, consisting of universities between the 1st and 10th physical therapy course of estácio ponta negra, over 18 years of age, who are not present in the application of the questionnaires, it is necessary to use the medicine of the analgesic type. the volunteers are evaluated through the hit-6 and sf-36 questionnaires, after a selection of pain evaluation, pgs and algometry. the randomization will consist of 4 groups, after a consultation and an immediate re-evaluation and a second time and a new intervention and re-evaluation. a descriptive and inferential statistics will be performed through the spss 20.0 program. the normality of the data is observed by the kolmogorov-smirnov (ks) test. for a comparison between groups whose parametric data are applied or anova test with post hoc tukey comingue of significance of 5% (p \<0.05). it is believed that the use of the association of myofascial release techniques and percutaneous microelectronics promotes greater benefits in tension headache.


Eligibility criteria:
inclusion criteria: * be over 18 years old, they will be present at the time of ordering, not being pregnant and not taking analgesic medication at least 24 hours before the intervention. exclusion criteria: * more than 20% of the questionnaire data are incomplete and if during the research the volunteer presents some discomfort.

Keywords: percutaneous microelectrolysis physiotherapy
examining the individual response to a restricted sodium diet in hypertensive patients

Conditions: Hypertension

Summary: excessive dietary sodium intake is an independent risk factor for hypertension and cardiovascular disease. a vast array of efforts have tried to reduce sodium consumption based on evidence indicating a public health benefit. yet this benefit has been questioned, mainly based on studies showing variability in individual responses to a sodium-restricted diet (srd). the effects of an srd on blood pressure vary, and adherence to an srd is not optimal. the original sodium watchers program (r01nr012967) was developed and implemented by dr. misook chung (university of kentucky). in this pilot study, the modified sodium watchers program will propose improving adherence to an srd through education and digital self-monitoring for daily sodium intake and blood pressure. in addition, few studies have examined individuals' metabolic responses to the srd. in a secondary analysis, we further will examine genetic variants associated with salt sensitivity and whether such a genetic component is associated with sodium excretion and bp control. a total of 40 hypertensive patients will be randomly assigned to the intervention (n=20) or control group (n=20). the intervention group will receive 8-week education sessions remotely using a video conferencing program. all participants will collect a 24-hour urine specimen for sodium excretion and a total of 4.0ml of peripheral blood will be drawn for salt sensitivity during baseline visit. all participants will be asked to log their activities in real-time, including food intake and in-home bp monitoring using fitbit and accompanied mobile app and bp monitor.


Eligibility criteria:
inclusion criteria: * systolic blood pressure of 120-159 mmhg or diastolic blood pressure of 80-99 mmhg, whether or not taking blood pressure medications. * smartphone with a data plan * valid email address * willing and able to participate in online study videoconferencing visits (zoom) * reads and writes in english exclusion criteria: * participating in another related research study * cardiovascular disease event (e.g. stroke, myocardial infarction) in prior 6 months * active cancer * recent hospitalization due to psychiatric condition or event * pregnancy or breastfeeding - current or planned during the study period * documented dementia * prisoners * diabetes diagnosis * heart failure diagnosis
fdg-pet imaging in young cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: the purpose of this research is to determine how a person's lungs will uptake \[18f\]fluorodeoxyglucose (fdg), as measured with positron emission tomography (pet) scanning in young cystic fibrosis (cf) patients.

our recent study in cf adults, supplemented by recent pre-clinical and clinical studies by our group suggests that labeled fluorodeoxyglocose-based positron emission tomography (fdg-pet) imaging may be a valuable quantitative biomarker of lung inflammation. the proposed study would validate our earlier findings, but in a younger patient population. the implications of such a test could be highly significant for both the testing of promising new anti-inflammatory agents and for patient management decisions. to capitalize on this exciting opportunity, the critical next step is to show that we can identify a cohort of young cf patients with both stable lung function and normal (or near normal) fdg-pet imaging studies. similar patients, then, would become the subjects for a future prospective cohort study to determine if fdg-pet imaging can in fact serve as a predictor of future changes in lung function.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cystic fibrosis * age 12 to 21 years old, of either gender, any race or ethnicity * stable recent pulmonary status (defined as no new pulmonary symptoms, new antibiotic use, or hospitalization for pulmonary symptoms for at least 1 month). * we will permit patients treated with the macrolide antibiotic, azithromycin, to participate in this study. azithromycin has recently become a virtual standard of care in cf, based on small but reproducible improvements in pulmonary function over 4 months of treatment with this drug. the mechanism of benefit is uncertain, but an anti-inflammatory effect has been suggested. the high prevalence of use means that a study without azithromycin would likely require a wash-out period, without data about the appropriate duration for such a wash-out, or whether inflammatory markers would reverse during that time. exclusion criteria: * failure to obtain informed consent * positive pregnancy test or lactation * currently enrolled in another study involving radioisotopes or an investigational drug * recent (within 30 days of screening) hospitalization for any reason * new antibiotic use (within 30 days of screening). * patient incapable of lying still and supine within the pet/computed x-ray tomography (ct) scanner for 90 minutes. * patient incapable of completing other testing procedures (e.g., pft, induced sputum) * patient with serum glucose greater than 150 mg/dl at time of pet imaging study * patient incapable of fasting for 4 to 6 hrs prior to pet imaging study
detection of the most common microorganism of infective endocarditis in assiut university hospital

Conditions: Infective Endocarditis

Summary: indocarditis is an endogenous infection acquired when organisms entering the blood stream establish on the heart valves, therefore, any bacteremia can potentially result in endocarditis. infective endocarditis is an uncommon disease that often presents as pyrexia of unknown origin. the mortality rate in endocarditis was very high before the antibiotic era, even now a day, the mortality rate is around 20%(1).a variety of microorganisms can cause ie; staphylococci and streptococci account for the majority of cases. staphylococcal ie is a common cause of healthcare-associated ie ; streptococcal ie is a common cause of community-acquired ie. common bacterial pathogens include staphylococcus aureus , viridans group streptococci , enterococcus, coagulase-negative staphylococci , streptococcus bovis , other streptococci , gram-negative bacteria, hacek organisms in this category include a number of fastidious gram-negative bacilli: haemophilus aphrophilus(subsequently called aggregatibacter aphrophilus and aggregatibacter paraphrophilus); actinobacillus actinomycetemcomitans (subsequently called aggregatibacter actinomycetemcomitans); cardiobacterium hominis; eikenella corrodens; and kingella kingae , and fungi (1,2). a variable proportion of ie remain blood culture- negative (1-4). most clinically significant bacteremias are detected within 48 hours; common and fastidious pathogens (such as members of the hacek group) may be detected within five days of incubation with modern automated blood culture detection systems. the optimal volume of blood for each blood culture in adults is 20 ml. zoonotic agents, such as coxiella burnetii, brucella spp., and bartonella spp. were frequently detected in north africa and identified as causes of infective endocarditis (ie) in egypt (3,4).blood culture is the most important investigation for diagnosing infective endocarditis andto know the prevalence rate of different bacteria and their antibiotic sensitivity pattern.positive blood culture is the cornerstone of microbiological diagnosis of ie; three sets of blood cultures detect 96 to 98 percent of bacteremia. at least three sets of blood cultures should be obtained from separate venipuncture sites prior to initiation of antibiotic therapy. patients with ie typically have continuous bacteremia; therefore, blood cultures may be collected at any time and need not necessarily be obtained at the time of fever or chills. material and method a total of 150 blood cultures were received from 50 clinically diagnosed cases of bacterial endocarditis . blood sample was collected under all aseptic precautions.


Eligibility criteria:
inclusion criteria:patients that are clinically diagnosed as infective endocarditis before starting antibiotics exclusion criteria:patients that receive antibiotics before taking the blood sample
acute appendicitis: the influence of c-reactive protein and leucocytes on clinical decision-making

Conditions: Acute Appendicitis

Summary: aim: to investigate if the results of crp and leucocytes had any positive or negative influence on the surgeon's decision-making when handling patients with suspected aa.

a prospective observational cohort study including patients (≥15 years of age) admitted on suspicion of aa. the surgeons were instructed to perform their physical examination and register whether they found the patient more or less than 50% likely to have aa. thereafter, the surgeons had to assess the blood results and reevaluate their diagnosis. the surgeon's diagnosis before and after was compared to the final diagnosis defined by surgical findings or follow up. gold standard was any degree of appendicitis on histology.

Eligibility criteria:
acutae abdominal pain suspect for acute appendicites
guilford genomic medicine initiative (ggmi)

Conditions: Breast Cancer; Ovarian Cancer; Colon Cancer; Thrombophilia

Summary: * genomic medicine, using genetic information to improve health outcomes, is heralded as the answer to rising medical costs by focusing on prevention and tailored care. despite its potential, little investigation has focused on how genomic medicine can be applied in health care. to be effective, it requires new ways to learn, deliver, and communicate medical information. it will also raise new ethical questions. * the overall goal of guilford genomic medicine initiative (ggmi) is to identify the specific challenges in "re-structuring" an existing medical system to integrate genomic medicine, and create solutions that can be used by other medical systems, such as the extensive military medical care system. to accomplish this goal, ggmi includes the development of a large-scale genomic medicine education initiative targeted at the community, providers, and patients, and a clinical systems model to implement strategies to facilitate the integration of genomic medicine into several pilot practices.


Eligibility criteria:
inclusion criteria: * all patients scheduled for an upcoming well or new visit within the next 3 weeks with their primary care physician (at the two implementation clinics). exclusion criteria: * non-english speaking * not consentable * adopted

Keywords: primary care family history risk stratification cancer thrombosis
study to determine the effect of bms-791325 on the ecg qtcf interval in healthy subjects

Conditions: Hepatitis C

Summary: the purpose of this study is to determine whether bms-791325 has an effect on the electrocardiogram (ecg) interval qt corrected for fridericia's method (qtcf).

primary purpose: other: this phase 1 study is a clinical pharmacology thorough qt study.

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * healthy men and women, ages 18 to 49 yr old * bmi 18 to 32 * women must not be pregnant or breastfeeding exclusion criteria: * any significant acute or chronic medical illness * a personal history of clinically relevant cardiac disease, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for torsades de pointes (eg, heart failure) * history of hypokalemia, personal history or family history of prolonged qt interval, or family history of sudden cardiac death at a young age * history of biliary disorders, including gilbert's disease or dubin-johnson disease * inability to swallow multiple tablets consecutively * any of the following on 12-lead electrocardiogram (ecg) prior to study drug administration: pr ≥ 210 msec, qrs ≥ 120 msec, qt ≥ 500 msec, qtcf ≥ 450 msec, heart rate (hr) \< 45 bpm * second or third degree heart block prior to study drug * positive urine screen for drugs of abuse * positive blood screen for hepatitis c antibody, hepatitis b surface antigen, or human immunodeficiency virus (hiv)-1, -2 antibody * any of the following lab results outside of the ranges specified below prior to dosing: alanine aminotransferase (alt) \> upper limit of normal (uln), aspartate aminotransferase (ast) \> uln, total bilirubin \> uln, direct bilirubin \> uln, creatinine \> uln, serum potassium \< lower limit of normal (lln), serum magnesium \< lln * history of allergy to moxifloxacin, bms-791325, nonstructural protein 5b (ns5b) non-nucleoside inhibitors or related compounds
the effects of a synbiotic addition on eradication therapy of helicobacter pylori infection in children

Conditions: Helicobacter Pylori Infection

Summary: the aim of the study is to evaluate the effects of the synbiotic bifidobacterium animalis ssp. lactis b94 plus inulin addition to the standard triple therapy on helicobacter pylori infection eradication rates in children.

the study aims to evaluate the effects of the synbiotic bifidobacterium animalis ssp. lactis b94 plus inulin addition to the standard triple therapy on the eradication rates of helicobacter pylori (h. pylori) infection in children. the subjects are children between 6 to 16 years old who had biopsy proven h. pylori infection. the subjects will be randomly classified into two groups. the first group will receive the standard triple therapy consisting of amoxicillin oral tablet (50 mg/kg/day) + clarithromycin oral tablet (15 mg/kg/day) + omeprazole oral capsule (1mg/kg/day). the second group will receive the standard triple therapy and bifidobacterium animalis ssp. lactis b94 (5000000000 colony forming units/dose) plus inulin (900 mg) containing sachet for 14 days, concurrently. eradication will be determined by 14-carbon-urea breath test 4-6 weeks after therapy discontinuation. the eradication rates, the occurrence of side effects and the alterations of initial symptoms will be compared between the groups.

Eligibility criteria:
inclusion criteria: * children who are investigated by a standard esophagogastroduodenoscopy (egd) for gastrointestinal symptoms those suggesting of an organic disease such as chronic abdominal pain, unexplained nausea and/or vomiting, severe regurgitation, gastrointestinal bleeding, unexplained weight loss, or chronic diarrhea and who are found to be h. pylori positive in gastric biopsies are included in the study. exclusion criteria: * patients who were treated for h. pylori infection previously, or who used an antimicrobial agent, bismuth, a non-steroid anti-inflammatory drug, or any form of gastric acid suppressor during the eight weeks prior to egd, or who had history of major gastrointestinal surgery, chronic renal or hepatic disease and who were known to have drug allergy were excluded from the study.

Keywords: helicobacter pylori infection children synbiotic standard triple therapy